局灶高强度聚焦超声部分腺体消融治疗局限性前列腺癌:英国单中心中期结局报告
本研究报道了英国单中心采用局灶高强度聚焦超声(HIFU)消融治疗显著性单侧前列腺癌的中期结局,共纳入107例男性,88%为中高危疾病,中位随访30个月,无临床显著复发需额外手术的比例为85.5%,术后并发症包括14%新发勃起功能障碍,作者认为肿瘤控制可接受且并发症少,但需进一步研究确立其作为根治性治疗低并发症替代方案的地位。
要点
- 107例男性接受局灶HIFU,88%为中高危前列腺癌,中位随访30个月。
- 无临床显著复发需额外手术的比例为85.5%,8%出现生化复发,11%需辅助治疗。
- 术后新发勃起功能障碍14%,1%新用尿垫,1.9%尿道狭窄,2.8%行HIFU后TURP。
核心结论
- 在精心选择的局灶HIFU患者队列中,结果提示肿瘤控制可接受且术后并发症少,但需进一步研究确立该技术作为根治性治疗低并发症替代方案的地位。
研究设计与样本
- 单中心报告局灶HIFU治疗显著性单侧前列腺癌的中期结局,共107例男性,采用Sonablate设备进行局灶消融。
主要发现
- 88%为中高危疾病,HIFU前平均PSA为7.7,31%为高体积Gleason 6,55%为Gleason 3+4,13%为Gleason≥4+3。
- 54例接受半腺消融,10例接受局灶消融,43例接受象限消融。
- 中位随访30个月,PSA降至平均71%最低点,8%出现生化复发,11%需辅助治疗。
- 无临床显著复发需额外手术(包括再次HIFU)的比例为85.5%。
- 术后并发症包括1%新用尿垫、1.9%尿道狭窄、2.8%HIFU后TURP、14%新发勃起功能障碍。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report our intermediate outcomes of the use of focal ablation for treating significant unilateral prostate cancer. This technique was adopted in our center 10 years ago. With improving diagnostic accuracy of index prostate cancer lesions and a low side-effect profile, use of focal high intensity focused ultrasound (HIFU) ablation is increasing. METHODS: Patients were diagnosed using prostate specific antigen (PSA), multiparametric magnetic resonance imaging, and template transperineal biopsies. Focal ablation of significant cancer was performed with the Sonablate device. Follow-up consisted of magnetic resonance imaging scanning, PSA, validated questionnaires, biopsy for cause, and redo HIFU if required as part of the treatment strategy. RESULTS: A total of 107 men underwent focal HIFU. In total, 88% had intermediate/high risk disease, and the mean pre-HIFU PSA was 7.7. A total of 31% had high volume Gleason 6 disease, 55% had Gleason 3+4 disease, and 13% had Gleason ≥ 4+3 disease. In total, 54 men received a hemiablation, 10 a focal ablation, and 43 a quadrant ablation. Median follow-up was 30 months, subjects' PSA dropped to an average 71% nadir. A total of 8% had biochemical recurrence and 11% required adjuvant treatment. Freedom from additional procedures for clinically significant recurrent disease, including redo-HIFU, was 85.5%. Postoperative complications included 1% new use of pads, 1.9% urethral stricture, 2.8% post-HIFU TURP, and new onset ED of 14%. CONCLUSION: In a carefully chosen cohort of patients for focal HIFU our results suggest acceptable oncological control with minimal postoperative morbidity. Further studies are required to establish this technique as a less morbid alternative to radical therapy.
引用
- Johnston MJ, Emara A, Noureldin M, et al. Focal High-intensity Focussed Ultrasound Partial Gland Ablation for the Treatment of Localised Prostate Cancer: A Report of Medium-term Outcomes From a Single-center in the United Kingdom. Urology. 2019. PMID: 31449831. doi:10.1016/j.urology.2019.06.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。